Researchers analyzed 11 different studies to understand weight outcomes after stopping anti-obesity medications called ...

Researchers in a recent study discovered that people taking medications to help them lose weight might experience weight gain ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Zepbound targets two hormones (GLP-1 and GIP), while Wegovy targets only GLP-1, AP reported. “Two drugs together can produce better weight loss,” said lead study author Dr. Louis Aronne of ...

A new study shows that people taking Zepbound lost about 50% more weight than those using Wegovy. Zepbound led to 50% more weight loss than Wegovy, study says Skip to main content Skip to main content ...

Patients in the study who took Zepbound were twice as likely as the Wegovy group to lose at least 25% of their body weight. About four-fifths of Zepbound patients lost at least 10%, compared to ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Zepbound helped patients lose 50 pounds, compared to 33 pounds with Wegovy. The study showed Zepbound users lost 20% of body weight. Both drugs caused some mild stomach-related side effects ...